ArticleInternational ophthalmology2026
Intravitreal sustained-release dexamethasone implant for the treatment of postoperative cystoid macular edema following vitrectomy.
Article in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimPrevious findings have demonstrated that intravitreal sustained-release dexamethasone (DEX) implants improve functional and anatomical outcomes in patients with cystoid macular edema (CME) following cataract surgery; however, data on the influence of different surgical indications remain limited. This study aims to evaluate the efficacy of DEX implants in patients with persistent postoperative CME following vitrectomy, and to assess differences in treatment response regarding surgical indication, phakic status, and prior treatment received before DEX.
methodsIn this single-center study, we retrospectively reviewed data from 57 patients (57 eyes) who received a DEX implant for persistent postoperative CME following vitrectomy; main outcome measures were change in best corrected visual acuity (BCVA) and central retinal thickness (CRT). We then measured the effect of treatment outcomes across subgroups of patients according to surgical indication (rhegmatogenous retinal detachment vs. epiretinal membrane), phakic status, and prior receipt of subtenon triamcinolone.
resultsPatient eyes receiving a DEX implant achieved a significant improvement in both functional and anatomical outcomes: BCVA gain, 0.53 to 0.47 logMAR (p = 0.0180); CRT reduction, 453.5 µm to 381.6 µm (p < 0.0001). The mean number of DEX implants received was 1.74, with no significant differences observed between patient subgroups. Subgroup comparisons did not show any significant impacts on BCVA or CRT by either surgical indication or type of surgery.
conclusionSustained-release DEX implants provided immediate and lasting functional and anatomical benefits in patients with persistent postoperative CME. Outcomes such as the required number of DEX implants or treatment response were not significantly impacted by subgroup factors.
Indexed as
Identifiers
41886138What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.